Speaker illustration

Mr Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

I’m a physician at the National Center for Tumor Diseases (NCT) Heidelberg. I received my medical degree with distinction from Heidelberg University. Simultaneously, I obtained a M.Sc. & B.Sc. in Management & Technology (major in biochemistry and finance & accounting) with high distinction from TU Munich and MIT. Further, I graduated with an M.Sc. in health economics from the LSE. My previous work experience in consulting, venture capital, private equity, and finance focused on projects in the biotech and healthcare industry. Over the past three years, I (co-)authored over 50 publications in leading medical journals (e.g. BMJ, JCO) and conferences (e.g. ESMO, ASCO, ESC). My research focuses on oncology, drug development, cardiology, clinical trials, and health policy.

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness


Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb